Plasma Biomarkers and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: New Tools for Better Patient Selection?

Abstract

Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for patients with non-small cell lung cancer (NSCLC). Although some patients can experience important response rates and improved survival, many others do not benefit from ICIs developing hyper-progressive disease or immune-related adverse events. This underlines the need to select biomarkers for ICIs use in order to better select patients. There is currently no universally validated robust biomarker for daily use of ICIs. Programmed death-ligand 1 (PD-L1) or tumor mutational burden (TMB) are sometimes used but still have several limitations. Plasma biomarkers are a promising approach in ICI treatment. This review will describe the development of novel plasma biomarkers such as soluble proteins, circulating tumor DNA (ctDNA), blood TMB, and blood microbiome in NSCLC patients treated with ICIs and their potential use in predicting response and toxicity.

• Authors: Adrien Costantini, Paul Takam Kamga, Coraline Dumenil, Thierry Chinet, Jean-François Emile, Etienne Giroux Leprieur
• Journal: Cancers (Cancers (Basel)) Vol. 11 Issue 9 (Aug 29 2019) ISSN: 2072-6694 [Print] Switzerland
• PMID: 31470546 (Publication Type: Journal Article, Review)